Rifampicin News and Research

RSS

Researchers Recreate Chemically Regulated Actin Polymerization to Study Membrane Dynamics

A synthetic platform that uses dimerization modules consisting of chemical proteins to precisely control the polymerization of actin and demonstrate symmetry breaking.

19 Jun 2024

Integrative genomic study identifies two new potential drug targets in Mycobacterium tuberculosis

Researchers used existing whole genome sequences of M. tuberculosis and conducted a pangenomic analysis to identify potential drug targets.

28 May 2024

MAGE Technology Helps Reveal the Potency of Antibiotics

By substituting each of the 20 amino acid alternatives found in nature for one of the 38 amino acid components that make up the rifampicin binding site on E. coli, the study authors were able to produce 760 distinct RNAP mutants. The development of this mutant pool was then examined under various circumstances, including rifampicin therapy.

31 Aug 2023

New Strain of Marine Bacteria with Distinct Characteristics

Researchers discovered a new type of marine bacteria with distinct traits on the ocean floor.

30 Aug 2023

Novel framework provides solutions to evade detoxification networks

Scientists at St. Jude Children's Research Hospital have demonstrated how drug makers can avoid two key problems: toxicity and resistance. The researchers made slight changes to a small molecule to reduce its metabolism and elimination by the cellular detoxification network regulated by the pregnane X receptor (PXR). This research provides a framework to develop solutions to the long-standing issue of how to evade detoxification networks using medicinal chemistry. The findings were published today in Proceedings of the National Academy of Sciences.

1 Mar 2023

Researchers discover antibiotic resistance genes in M. tuberculosis

More than 10,000 different Mycobacterium tuberculosis bacteria isolated from 23 different countries were subjected to a thorough investigation, which uncovered new genes linked to resistance to 13 first- and second-line novel and repurposed medicines.

11 Aug 2022